Let me guess. You've read enough about GLP-1 medications to know they're not snake oil, you've heard a friend-of-a-friend lose a meaningful amount of weight, and now you're trying to figure out what an actual medically-supervised program looks like — versus someone just mailing you a vial and wishing you luck.
Fair question. Let's get into it.
The Short Answer, Up Front
A well-designed GLP-1 program has four moving parts: eligibility screening, baseline labs and medical review, prescription with a structured dose titration schedule, and ongoing clinical follow-up. The medication does the biological work. The program is what keeps that work safe, sustainable, and honestly — bearable, because side effects hit differently when nobody's answering your questions.
At tb2.health, we built our program around those four components because skipping any of them is where self-directed GLP-1 use tends to go sideways. I'll walk through the mechanism first, then the program design.
What GLP-1 Medications Actually Do
I'm not a clinician, but I've spent an embarrassing number of hours reading the literature — first as tb2.health's co-founder, and honestly before that as our "patient zero." So here's the mechanism in plain English.
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does a few things at once:
- Stimulates insulin release when blood sugar rises
- Suppresses glucagon, the hormone that tells your liver to dump sugar into your bloodstream
- Slows gastric emptying — food sits in your stomach longer, so you feel full longer
- Signals satiety in the brain, quieting the constant "what's next to eat" chatter that many people with obesity describe as "food noise"
GLP-1 receptor agonist medications are engineered analogs of that natural hormone, designed to last days instead of minutes. The NIH has a solid overview of the endocrine pathway if you want to go deeper.
The practical result: you eat less because you're genuinely less hungry, your blood sugar stabilizes, and — over time, with a proper protocol — your body's set point starts to shift.
Not magic. Biology.
Semaglutide vs. Tirzepatide: A Brief Clinical Comparison
Two molecules dominate the current landscape. They're related but not identical.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor activity | GLP-1 only | GLP-1 and GIP (dual agonist) |
| Dosing frequency | Weekly injection | Weekly injection |
| Typical titration window | ~16–20 weeks to target dose | ~20–24 weeks to target dose |
| Clinical trial average weight reduction | ~15% at 68 weeks (STEP trials) | ~20.9% at 72 weeks (SURMOUNT trials) |
| Side effect profile | Primarily GI (nausea, constipation) | Primarily GI, similar pattern |
Tirzepatide's second mechanism — GIP receptor activity — appears to amplify the metabolic and appetite effects for many patients. The SURMOUNT-1 trial in the New England Journal of Medicine is the clearest published comparison of what tirzepatide can do at target dosing.
That said: the "better" molecule is the one that's right for your history, tolerance, and clinical picture. Some patients tolerate one and not the other. Some respond dramatically to semaglutide and modestly to tirzepatide, or vice versa. That decision belongs with your prescribing clinician, not a comparison table on the internet — including this one.
What a Real Medically-Supervised Program Should Include
Here's where a lot of "GLP-1 programs" quietly fall short. If a service can't clearly explain each of the following, that's a flag.
1. Eligibility Screening
Before anything else, a clinician needs to confirm you're a candidate. That typically means:
- BMI thresholds (or BMI plus comorbidities like type 2 diabetes, hypertension, sleep apnea, or PCOS)
- Personal and family medical history
- Contraindications — personal or family history of medullary thyroid carcinoma, MEN2, active pancreatitis, and a handful of others
- Current medications and potential interactions
This isn't a formality. It's the difference between a treatment plan and a liability.
2. Baseline Labs and Medical Review
A responsible program orders baseline bloodwork before writing a prescription. At minimum: comprehensive metabolic panel, lipid panel, HbA1c, and — depending on history — thyroid function and other markers. Labs establish a starting point and surface anything that needs to be addressed before starting therapy.
3. Structured Dose Titration
GLP-1 medications start low and step up on a defined schedule. This isn't a marketing detail; it's the single biggest factor in whether side effects are manageable. Starting too high is how people end up quitting in week three, convinced the medication doesn't work for them.
A proper titration schedule:
- Begins at a low introductory dose
- Steps up at defined intervals (typically every 4 weeks)
- Adjusts based on how you're actually tolerating it — not on a rigid calendar
- Has a clear target maintenance dose based on response
4. Ongoing Clinical Follow-Up
The prescription isn't the program. The program is what happens between prescriptions.
That means scheduled check-ins with a clinician, a channel to ask questions when side effects surface at 9pm on a Tuesday, periodic lab reassessment, and adjustments as your body adapts. If a "program" hands you a vial and disappears — that's a pharmacy transaction, not medical care.
How tb2.health Designed Our Program Around These Components
I'll be direct here: we built tb2.health because I went through this journey myself and saw where the market was failing people. Either you got white-glove care at a $15,000/year concierge clinic, or you got a chatbot and a shipment. Nothing decent in the middle.
Our program is structured around the four components above:
Screening and intake happen through a detailed medical questionnaire reviewed by a licensed clinician — not an algorithm making the final call.
Baseline labs are ordered before any prescription is written. If your history warrants additional workup, we do it. If you're not a candidate, we tell you plainly and often refer you elsewhere.
Titration is individualized. The starting dose and step-up cadence are set by your clinician based on your baseline, tolerance, and response. Feeling rough at week four? We hold. Cruising? We proceed on schedule. This is where the phrase "GLP-1 dose titration explained" stops being a search query and starts being a weekly clinical decision.
Follow-up is built in, not an upsell. Regular check-ins, a Patient Care Coordinator (PCC) you can actually reach, and periodic lab reassessment as you progress.
We also work with operational partners like Growaton on the infrastructure side so that the patient-facing experience — messaging, scheduling, refills — doesn't get in the way of the clinical relationship.
A Note on Clinical Judgment
Everything above is program design. The medical decisions inside it — whether you're a candidate, which molecule fits your history, how fast to titrate, when to hold or adjust — belong to a licensed clinician who has your full picture in front of them.
If you're reading this and comparing programs, that's the question to ask: who is actually making my clinical decisions, and how often will I hear from them? If the answer is fuzzy, keep looking.
Where to Go From Here
If you've read this far, you're not looking for a miracle. You're looking for a program that treats you like a patient instead of a subscription. That's the bar we set for ourselves, and it's a bar you should hold every provider to — including us.
You can see how our program is structured at tb2.health, or start with the eligibility questionnaire if you want to know whether this is even the right conversation for you to be having. Either way — you're already doing the work by understanding the mechanism before the medication. That instinct will serve you well no matter where you enroll.